Introduction
============

Acute ST-segment elevation myocardial infarction (STEMI), with unexpected onset, high sudden death rate and poor prognosis, is a critical acute coronary syndrome. The implementation of percutaneous coronary intervention (PCI) has lead to a reduction in the mortality of STEMI ([@b1-etm-0-0-3693]). However, the stress response of patients themselves and enhanced antithrombotic drugs have increased the risks of gastrointestinal bleeding ([@b2-etm-0-0-3693]). Thus, it is clinically vital to use proton pump inhibitors (PPIs) to prevent ulcers resulting from stress.

Previous findings have shown that PPIs possibly interact with clopidogrel and reduce antiplatelet effects, and thus increase the risk of death and re-hospitalization of patients ([@b3-etm-0-0-3693],[@b4-etm-0-0-3693]).

The present study aimed to investigate the effects of the short-term application of pantoprazole together with the co-treatment of aspirin plus clopidogrel for myocardial infarction with aspirin plus clopidogrel, providing a theoretical basis that may be utilized in the clinic.

Materials and methods
=====================

### Clinical data

A total of 207 acute patients who showed primary symptoms of STEMI and successfully underwent emergent PCI treatment during hospitalization in the Department of Cardiology of Xuzhou Central Hospital (Jiangsu, China) from December, 2012 to December, 2014, were randomly divided into two groups of dual antiplatelet therapy (aspirin plus clopidogrel). The test group (PPIs), which received co-treatment of aspirin and clopidogrel and pantoprazole, comprised 123 patients (69 men and 54 women), with an average age of 59.32±9.14 years. The control group (treatment with aspirin and clopidogrel), comprised 84 patients (48 men and 36 women), with an average age of 58.47±10.06 years.

The selected patients adhered to the WHO diagnostic criteria of STEMI: i) typical chest pain duration of \>30 min; ii) ST-segment elevation in electrocardiogram in the lead of at least two limbs or two precordial leads \>1 mm; and iii) dynamic changes in serum cardiac enzymes with surgery indications for emergent PCI. Exclusion criteria for the patients were: i) with other heart diseases; ii) with severe heart failure (Killip grade III--IV) and liver and kidney dysfunction; iii) combined with acute and chronic infections, gastrointestinal ulcers, blood diseases, malignancies, rheumatic connective tissue diseases and other immune system disorders; iv) with recent surgery or trauma with previous PCI surgery; v) with diabetes and other endocrine diseases; and vi) with cerebrovascular and peripheral vascular diseases and other diseases.

### Antiplatelet medicine

Immediately after admission the patients received (before PCI) aspirin tablets (500 mg) by chewing and clopidogrel orally at a loading dose of 600 mg. The patients were then postoperatively administered clopidogrel at a dose of 75 mg and Bayer aspirin (Yangtze River Pharmaceutical Co., Ltd., Taizhou, China) at 100 mg, both by oral administration, daily, and enoxaparin sodium was used concomitantly for 5 to 8 days.

### Application of pantoprazole in PPIs group

Patients in the PPIs group were treated with intravenous injection of pantoprazole at 40 mg immediately after admission for 3 to 5 days, on a daily basis. followed by oral administration at 40 mg, daily, until discharge.

### Administration of other medicines

Patients showing relevant indications during hospitalization received statins, β-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) or other medicine for the treatment.

### Observation of gastrointestinal bleeding events

Gastrointestinal bleeding was observed in the two groups during hospitalization. A gastrointestinal ulcer due to stress was identified from one of the following signs especially during the first week of hospitalization: vomit; brown, red or black gastric juice, or bloody stool; black stool in parallel with positive result of occult blood test; unexplained decline in hemoglobin ([@b5-etm-0-0-3693]); and recessive bleeding without the abovementioned signs: positive results only in occult blood test, no significant bleeding; severe gastrointestinal bleeding: obvious vomiting of blood, bloody stool or sharp decline of hemoglobin; minor bleeding: bleeding between recessive and gastrointestinal bleeding.

### Observation of major adverse cardiac events

During the first 6 months of illness (including the hospitalization period), the major adverse cardiac events (MACEs) of the two groups were recorded, including secondary onset of heart failure, severe arrhythmias (ventricular tachycardia, ventricular fibrillation, atrioventricular block at degree II or above III), infarction after angina, recurrent myocardial infarction, and cardiac death.

### Statistical analysis

SPSS 18.0 (Chicago, IL, USA) software was used for statistical analysis. Measurement data are presented as mean ± standard deviation and the countable data were analyzed using the Chi-square test (χ^2^). P\<0.05 was considered statistically significant.

Results
=======

### Comparison of baseline data

There were no statistically significant differences (p\>0.05) for gender, age, body mass index (BMI), smoking, drinking history, concomitant diseases (hypertension, hyperlipidemia), and the biochemical criteria (blood routine examination, coagulation function, biochemistry full terms) of patients between the PPIs and control groups.

### Comparison of gastrointestinal bleeding events and MACEs

Gastrointestinal bleeding occurred in two cases (1.6%) of the PPIs group, including one case of occult bleeding and one case of minor bleeding, without severe gastrointestinal bleeding in this group. Additionally, there were 13 cases of gastrointestinal bleeding in the control group (15.5%), including 5 cases of recessive bleeding, 5 cases of minor bleeding and 3 cases of severe gastrointestinal bleeding. There were significant differences (p\<0.05) between the PPIs and control groups ([Table I](#tI-etm-0-0-3693){ref-type="table"}).

There were no statistical differences in the secondary onset of heart failure, severe arrhythmias (ventricular tachycardia, ventricular fibrillation, atrioventricular block at degree II or above III), infarction after angina, and recurrent myocardial infarction, as well as cardiac death in patients between two groups (all at p\>0.05), ([Table II](#tII-etm-0-0-3693){ref-type="table"}).

Discussion
==========

The administration of high doses of aspirin, clopidogrel and low molecular weight heparin in acute STEMI patients and their own perioperative stress response, particularly in patients undergoing PCI surgery, leads to a significantly increased risk of gastrointestinal bleeding ([@b6-etm-0-0-3693]). Numerous studies have shown its high incidence mainly during the first week of the course of disease ([@b7-etm-0-0-3693],[@b8-etm-0-0-3693]). To solve these problems, in the year 2008, the American Heart Association (AHA), American College of Cardiology Foundation (ACCF) and the American Society of Gastroenterology (ACG) jointly issued an 'Expert consensus to reduce the risk of gastrointestinal bleeding resulting from anti-platelet medicine and NSAIDS', suggesting that the patients with myocardial infarction should receive PPIs in parallel with antithrombotic therapy ([@b9-etm-0-0-3693]). That study indicated that the gastrointestinal bleeding events occurred in patients mainly during the first week after admission and pantoprazole significantly reduced the gastrointestinal bleeding event rate of patients with acute STEMI.

However, controversy exists regarding a possible interaction between PPIs and antithrombotic drugs. Gilard *et al* ([@b10-etm-0-0-3693]) designed a double-blind randomized controlled OCLA study and found that the administration of omeprazole together with antiplatelet PCI on day seven in patients resulted in a statistically lower platelet reactivity index (PRI) than the control group (p\<0.05), confirming that omeprazole reduced the inhibitory effect of platelet P2Y12 receptor by clopidogrel. However, the research results presented by FAST-MI showed that the combined treatment of PPI together with omeprazole did not affect the clinical efficacy of clopidogrel. The results of the present study show that the short-term coadministration of pantoprazole did not increase the incidence of MACE events, indirectly supporting the results of FAST-MI ([@b11-etm-0-0-3693]).

However, there are some limitations to the present study, such as short duration, and small sample size, which may cause somewhat statistical deviations and inaccurate long-term prognosis of patients. These issues remain to be clarified in our continual follow-up and future studies. Other authors have also shown that the different PPIs had a different impact on anti-platelet medicines. For example, lansoprazole exerted the strongest inhibitory effects on anti-platelet function while pantoprazole and rabeprazole played a less suppressive role partially because the degradation products of pantoprazole and rabeprazole had a stronger inhibition to CYP2C19 ([@b12-etm-0-0-3693]). However, that study only tested the short-time function of pantoprazole, and did not compare pantoprazole to other PPI drugs nor observed its effect on platelet function. These issues are to be investigated in subsequent studies.

In conclusion, the short-term application of pantoprazole reduced the risk of gastrointestinal bleeding but did not increase the incidence of MACE events in patients with acute STEMI, thus being worth extending clinically, especially for high-risk patients.

###### 

Comparison of gastrointestinal bleeding events between the two groups (%).

  Groups       Cases   No. (%) Gastrointestinal bleeding events                No. (%) Recessive bleeding                              No. (%) Minor bleeding                                  No. (%) Severe gastrointestinal bleeding
  ------------ ------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  PPIs         123     2 (1.6)^[a](#tfn1-etm-0-0-3693){ref-type="table-fn"}^   1 (0.8)^[a](#tfn1-etm-0-0-3693){ref-type="table-fn"}^   1 (0.8)^[a](#tfn1-etm-0-0-3693){ref-type="table-fn"}^   0 (0.0)^[a](#tfn1-etm-0-0-3693){ref-type="table-fn"}^
  Control      84      13 (15.5)                                               5 (6.0)                                                 5 (6.0)                                                 3 (3.6)
  χ^2^-value           14.245                                                  4.684                                                   4.684                                                   4.457
  P-value              0.000                                                   0.030                                                   0.030                                                   0.035

Compared to control group, p\<0.05. PPIs, proton pump inhibitors.

###### 

Comparison of MACEs between the two groups of patients (%).

  Groups       Cases   Secondary heart failure No. (%)   Severe arrhythmia No. (%)   Post-infarction angina No. (%)   Recurrent myocardial infarction No. (%)   Cardiogenic death No. (%)
  ------------ ------- --------------------------------- --------------------------- -------------------------------- ----------------------------------------- ---------------------------
  PPIs         117     12 (10.2)                         4 (3.4)                     23 (19.6)                        6 (5.1)                                   3 (2.5)
  Control      80      8 (10.0)                          3 (3.7)                     16 (20.0)                        4 (5.0)                                   2 (2.5)
  χ^2^-value           0.003                             0.015                       0.003                            0.002                                     0.001
  P-value              0.953                             0.902                       0.953                            0.968                                     0.978

MACEs, major adverse cardiac events; PPIs, proton pump inhibitors.
